I-Mab

IMAB

US44975P1030

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
1.81 ^USD	+1.12%		+2.55%	-4.74%

18/04	Verastem Names John Hayslip as Chief Medical Officer	MT
15/04	I-Mab Announces Chief Medical Officer Changes	CI

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

April 08, 2024 at 04:58 pm IST

ROCKVILLE - I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California.

Contact:

Tyler Ehler

Email: IR@imabbio.com

Latest news about I-Mab

Verastem Names John Hayslip as Chief Medical Officer	19/04	MT
I-Mab Announces Chief Medical Officer Changes	16/04	CI
I-Mab Completes Business Divestiture in China	03/04	MT
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04	CI
I-Mab Announces Executive Resignation	01/04	CI
Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	18/03	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	15/03	MT
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02	RE
I-Mab Divests China Operations, Shifts Focus to US Market	09/02	MT
ADRs Close Higher, Renalytix PLC Climbs 96.9%	09/02	DJ
Biotech firm I-Mab to divest China operations, shift focus to US	07/02	RE
Biotech firm I-Mab to divest China operations	07/02	RE
I-Mab Announces Board Changes , Effective February 10, 2024	07/02	CI
I-mab Biopharma Co., Ltd. agreed to acquire I-Mab Biopharma Co., Ltd. from I-Mab for $80 million.	07/02	CI
I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab	07/02	CI
I-Mab Announces Chief Financial Officer Changes	06/02	CI
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading	11/01	MT
ADRs Slump; FLJ Group Declines 21%	03/01	DJ
I-Mab(NasdaqGM:IMAB) dropped from NASDAQ Biotechnology Index	15/12	CI
I-Mab Says FDA Grants Breakthrough Therapy Designation for Felzartamab to Treat Kidney Disease	02/11	MT
I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy	02/11	CI
I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023	16/23/16	CI
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503	10/23/10	CI
AbbVie Terminates $3 Billion Cancer Drug Deal With Biotech Firm I-Mab	26/23/26	MT

Chart I-Mab

Duration

Period

More charts

Company Profile

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Companyâs pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.79 USD

Average target price

7.25 USD

Spread / Average Target

+305.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
I-MAB	-4.74%	144M
ELI LILLY AND COMPANY	+32.36%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	358B
MERCK & CO., INC.	+19.46%	328B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	165B

Other Pharmaceuticals

I-Mab

Equities

IMAB

US44975P1030

Pharmaceuticals

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Latest news about I-Mab

Chart I-Mab

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals